Hyperkalemia

• 

  Subject Areas on Research

  • A theoretical analysis of acute ischemia and infarction using ECG reconstruction on a 2-D model of myocardium. 
  • Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. 
  • Assessing the Impact of an Order Panel Utilizing Weight-Based Insulin and Standardized Monitoring of Blood Glucose for Patients With Hyperkalemia. 
  • Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. 
  • Cause Unknown, Treatment Uncertain, Outcome Poor: An Encounter With Kidney Failure in the Developing World. 
  • Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. 
  • Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists. 
  • Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. 
  • Dinucleotide repeat polymorphisms at the SCN4A locus suggest allelic heterogeneity of hyperkalemic periodic paralysis and paramyotonia congenita. 
  • Diuretic complications. 
  • Effect of Salt Substitution on Cardiovascular Events and Death. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. 
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Exchange transfusion using washed red blood cells reconstituted with fresh-frozen plasma for treatment of severe hyperkalemia in the neonate. 
  • General anesthesia and hyperkalemic periodic paralysis. 
  • Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. 
  • Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. 
  • Hyperkalemia in Heart Failure: Probably Not O"K". 
  • Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. 
  • Hyperkalemia: a review. 
  • Hyperkalemia: treatment options. 
  • Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. 
  • Label-free oxygen-metabolic photoacoustic microscopy in vivo. 
  • Life-threatening hyperkalemia after 2 days of ibuprofen. 
  • Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: an evaluation of the evidence. 
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 
  • Potassium Disorders: Hypokalemia and Hyperkalemia. 
  • Predialysis health, dialysis timing, and outcomes among older United States adults. 
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. 
  • Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go? 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. 
  • Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study. 
  • The electrophysiological effects of calcium channel blockade during standard hyperkalemic hypothermic cardioplegic arrest. 
  • The frequency of hyperkalemia and its significance in chronic kidney disease. 
  • The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. 
  • The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. 
  • Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. 
  • Treatment of hyperkalaemia using intravenous and nebulised salbutamol. 
  • Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. 
  • Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass. 
  • What's new in diuretic therapy. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology